Suven Life Sciences Ltd
NSE:SUVEN

Watchlist Manager
Suven Life Sciences Ltd Logo
Suven Life Sciences Ltd
NSE:SUVEN
Watchlist
Price: 117.47 INR -0.53% Market Closed
Market Cap: 25.6B INR
Have any thoughts about
Suven Life Sciences Ltd?
Write Note

Suven Life Sciences Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Suven Life Sciences Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Suven Life Sciences Ltd
NSE:SUVEN
Change in Working Capital
â‚ą105.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Divi's Laboratories Ltd
NSE:DIVISLAB
Change in Working Capital
-â‚ą9.8B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Change in Working Capital
â‚ą755.5m
CAGR 3-Years
-34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Change in Working Capital
-â‚ą226m
CAGR 3-Years
49%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Tarsons Products Ltd
NSE:TARSONS
Change in Working Capital
-â‚ą98.2m
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Change in Working Capital
-â‚ą203.5m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Suven Life Sciences Ltd
Glance View

Market Cap
25.6B INR
Industry
Life Sciences Tools & Services

Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.

SUVEN Intrinsic Value
2.1 INR
Overvaluation 98%
Intrinsic Value
Price

See Also

What is Suven Life Sciences Ltd's Change in Working Capital?
Change in Working Capital
105.1m INR

Based on the financial report for Sep 30, 2024, Suven Life Sciences Ltd's Change in Working Capital amounts to 105.1m INR.

What is Suven Life Sciences Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
48%

Over the last year, the Change in Working Capital growth was 48%.

Back to Top